A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us.

This article presents an example of how clinical trial data may be complemented by real-world evidence by reviewing pivotal clinical trial data for one direct oral anticoagulant (DOAC), along with an ...

Clinical trials aim to improve healthcare and medicines by trialing new drugs and analyzing their effects. However, is this aim for betterment reflected in advancing the methodology of clinical trials ...

An expert in gout clinical trials questions whether ethical considerations for such trials need updating to emphasize patient choice, dose alterations, and anti-inflammatory prophylaxis.

As the world becomes more digital, clinical research is evolving. One major change is the rise of decentralized clinical trials, or DCTs. Unlike traditional trials that require participants to visit ...

Recommendations for Interventional Trials (SPIRIT) 2025 guidelines published in The Lancet and commend the efforts to enhance transparency and rigour in clinical trial protocols.1,2 Accurate and ...

Clinical trial names span a broad range, from straightforward acronyms to more inspiring titles—see: Eli Lilly’s optimistically dubbed family of Triumph trials—to the downright ostentatious, like ...

The 6,000-square-foot unit will allow patients to participate in therapeutic studies without traveling to the main hospital, ...

Increasing the diversity of clinical trial participants is all the rage these days. The numbers tell the story: According to Food and Drug Administration data, in 2020 75% of trial participants were ...

Stony Brook Medicine opens its 6,000 sq. ft. Clinical Trials Unit in Commack, expanding access to advanced research and patient care studies ...

Correspondence to Dr Thomas Bandholm, Dept of Clinical Research, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre DK-2650, Denmark; thomas.quaade.bandholm{at}regionh.dk The REPORT guide ...

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.